DELRAY BEACH, Fla., May 4, 2026 /PRNewswire/ -- According to MarketsandMarkets, the Biologics Safety Testing is projected to grow from about USD 5.57 billion in 2026 to USD 9.66 billion by 2031, at a CAGR of 11.6%.
Browse 260 market data Tables and 60 Figures spread through 270 Pages and in-depth TOC on 'Biologics Safety Testing Market- Global Forecast to 2031'
Biologics Safety Testing Market Size & Forecast:
- Market Size Available for Years: 2025-2031
- 2026 Market Size: USD 5.57 billion
- 2031 Projected Market Size: USD 9.66 billion
- CAGR (2026-2031): 11.6%
Biologics Safety Testing Market Trends & Insights:
- By offering, in 2025, the product segment had the largest share of 41.9%.
- Pharmaceutical & biotechnology companies dominated the biologics safety testing products market in 2025 with a share of 56.0%.
- North America accounted for the largest market share, by region, in 2025: 43%.
Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=34624144
The growth of advanced modalities such as cell & gene therapies and mRNA products is a major driver of the biologics safety testing market. Additionally, the expanding pipeline of biologics and biosimilars, along with stringent and evolving regulatory requirements, is driving the market growth.
By offerings, The Service segment accounted for the largest share of the global biologics safety testing market in 2025.
Based on offerings, the biologics safety testing market is segmented into products and services. The services segment dominated the biologics safety testing market share in 2025, driven by increasing outsourcing to CROs and CDMOs, rising complexity of biologics, and the need for specialized expertise. The growing demand for end-to-end testing across development and manufacturing, along with stringent regulatory requirements, further supports the segment's leadership. Additionally, the expansion of cell and gene therapies and increasing biologics production continue to boost service adoption, reinforcing its dominant position in the global biologics safety testing market.
Request Sample Pages @https://www.marketsandmarkets.com/requestsampleNew.asp?id=34624144
By application, vaccine safety testing is estimated to be the fastest-growing service application segment in the biologics safety testing market.
The global biologics safety testing service market is segmented by monoclonal antibodies & therapeutic proteins safety testing, vaccines safety testing, cellular & gene therapy safety testing, blood & blood products safety testing, and other applications. During the forecast period, the vaccines safety testing segment is projected to be the fastest-growing in the biologics safety testing services market, driven by increasing global immunization programs, rising vaccine production, and the continuous development of new and improved vaccines. Stringent regulatory requirements for batch release and quality assurance further accelerate demand for comprehensive safety testing solutions.
North America accounted for the largest regional share in the global biologics safety testing market in 2025.
North America accounted for the largest share of regional revenues in the biologics safety testing market and remains the primary growth engine. The region's dominance is driven by a high concentration of leading biopharmaceutical companies, advanced research infrastructure, and strong regulatory oversight from agencies such as the FDA. Increasing biologics production, rapid adoption of cell and gene therapies, and a robust clinical trials landscape further support demand for safety testing. Additionally, significant public and private funding, along with widespread outsourcing to CROs and CDMOs, positions the US as a key hub for innovation and market growth.
Inquire Before Buying @https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=34624144
Top Companies in Biologics Safety Testing Market:
The Top Companies in Biologics Safety Testing Market include Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Lonza (Switzerland), FUJIFILM Corporation (Japan), Sartorius AG (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), Charles River Laboratories (US), bioMérieux (France), Maravai LifeSciences (US), WuXi AppTec (China), SGS Société Générale de Surveillance SA (Switzerland), Sotera Health (US), Samsung Biologics (South Korea), GenScript (US), Agilent Technologies, Inc. (US), Syngene International Limited (India), Eurofins Scientific (Luxembourg), Laboratory Corporation of America Holdings (US), Bio-Rad Laboratories, Inc. (US), and QIAGEN (Netherlands).
Browse Adjacent Markets: Biotechnology Market Research Reports & Consulting
Related Reports:
Monoclonal Antibody Therapeutics Market - Global Forecast to 2029
Vaccines Market - Global Forecast to 2030
Gene Therapy Market - Global Forecast to 2032
Cell Therapy Technologies Market - Global Forecast to 2030
Biosimilars Market - Global Forecast to 2035
About MarketsandMarkets
MarketsandMarkets has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore, which integrates research and provides ecosystem-wide visibility into revenue shifts.
MarketsandMarkets SalesPlay is an AI-driven Revenue Intelligence Co-Pilot designed to help revenue teams prioritize the right accounts, identify critical changes early, and surface opportunities ahead of demand, so pipeline builds naturally and deals close with greater consistency.
To find out more, visit www.MarketsandMarkets.com or follow us on Twitter, LinkedIn and Facebook.
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
Logo: https://mma.prnewswire.com/media/1868219/5909825/MarketsandMarkets_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/biologics-safety-testing-market-worth-9-66-billion-by-2031--marketsandmarkets-302761134.html
